APLT Key Statistics, Chart & Performance
The current stock price of APLT is 0.1002 USD. In the past month the price decreased by -54.03%. In the past year, price decreased by -84.73%.
APLT Latest News, Press Relases and Analysis
APLT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.24 | 388.16B | ||
| AMGN | AMGEN INC | 14.73 | 173.52B | ||
| GILD | GILEAD SCIENCES INC | 14.88 | 151.18B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.16 | 115.23B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.78 | 79.36B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 726.66 | 48.96B | ||
| INSM | INSMED INC | N/A | 35.00B | ||
| NTRA | NATERA INC | N/A | 32.62B | ||
| BIIB | BIOGEN INC | 10.7 | 26.26B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.86B | ||
| INCY | INCYTE CORP | 16.34 | 20.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18 | 20.46B |
Related stock screener links
About APLT
Company Profile
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. The company is headquartered in New York City, New York and currently employs 28 full-time employees. The company went IPO on 2019-05-09. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The firm is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). The company has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).
Company Info
APPLIED THERAPEUTICS INC
545 Fifth Avenue, Suite 1400
New York City NEW YORK 10017 US
CEO: Shoshana Shendelman
Employees: 28
Phone: 12122209226
APPLIED THERAPEUTICS INC / APLT FAQ
Can you describe the business of APPLIED THERAPEUTICS INC?
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. The company is headquartered in New York City, New York and currently employs 28 full-time employees. The company went IPO on 2019-05-09. The Company’s lead drug candidate, govorestat, is a central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including classic galactosemia, sorbitol dehydrogenase (SORD) deficiency and phosphomannomutase 2 (PMM2)-congenital disorder glycosylation (CDG). The firm is also developing AT-001, an investigational, ARI developed as an oral therapy for the treatment of diabetic cardiomyopathy (DbCM). The company has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type II diabetes. The Company’s pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, and has demonstrated strong retinal penetrance, for the treatment of diabetic retinopathy (DR).
What is the current price of APLT stock?
The current stock price of APLT is 0.1002 USD. The price increased by 0.5% in the last trading session.
Does APPLIED THERAPEUTICS INC pay dividends?
APLT does not pay a dividend.
How is the ChartMill rating for APPLIED THERAPEUTICS INC?
APLT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the market capitalization of APLT stock?
APPLIED THERAPEUTICS INC (APLT) has a market capitalization of 14.46M USD. This makes APLT a Nano Cap stock.
Can you provide the ownership details for APLT stock?
You can find the ownership structure of APPLIED THERAPEUTICS INC (APLT) on the Ownership tab.
APLT Technical Analysis
APLT Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to APLT. APLT may be in some trouble as it scores bad on both profitability and health.
APLT Financial Highlights
Over the last trailing twelve months APLT reported a non-GAAP Earnings per Share(EPS) of -0.1. The EPS increased by 93.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -52.77% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
APLT Forecast & Estimates
9 analysts have analysed APLT and the average price target is 0.26 USD. This implies a price increase of 154.49% is expected in the next year compared to the current price of 0.1002.
For the next year, analysts expect an EPS growth of 32.11% and a revenue growth 80.83% for APLT